David D L Bowtell
Overview
Explore the profile of David D L Bowtell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
6495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dicks E, Tyrer J, Ezquina S, Jones M, Baierl J, Peng P, et al.
Eur J Hum Genet
. 2025 Feb;
33(3):297-303.
PMID: 39939714
Rare, germline loss-of-function variants in a handful of DNA repair genes are associated with epithelial ovarian cancer. The aim of this study was to evaluate the role of rare, coding,...
2.
Nesic K, Krais J, Wang Y, Vandenberg C, Patel P, Cai K, et al.
Mol Cancer
. 2024 Aug;
23(1):158.
PMID: 39103848
PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance...
3.
Burdett N, Willis M, Pandey A, Twomey L, Alaei S, Bowtell D, et al.
Nat Commun
. 2024 Jul;
15(1):6069.
PMID: 39025846
Whole genome duplication is frequently observed in cancer, and its prevalence in our prior analysis of end-stage, homologous recombination deficient high grade serous ovarian cancer (almost 80% of samples) supports...
4.
Stiegeler N, Garsed D, Au-Yeung G, Bowtell D, Heinzelmann-Schwarz V, Zwimpfer T
Front Oncol
. 2024 Jun;
14:1387281.
PMID: 38894867
Approximately 50% of tubo-ovarian high-grade serous carcinomas (HGSCs) have functional homologous recombination-mediated (HR) DNA repair, so-called HR-proficient tumors, which are often associated with primary platinum resistance (relapse within six months...
5.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3481-3498.
PMID: 38837893
Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences...
6.
Bateman N, Abulez T, Soltis A, McPherson A, Choi S, Garsed D, et al.
NPJ Precis Oncol
. 2024 May;
8(1):97.
PMID: 38710993
No abstract available.
7.
Bateman N, Abulez T, Soltis A, McPherson A, Choi S, Garsed D, et al.
NPJ Precis Oncol
. 2024 Mar;
8(1):68.
PMID: 38480868
We performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade serous ovarian cancer (HGSOC) tissue specimens spanning a broad spectrum of purity....
8.
Burdett N, Willis M, Pandey A, Fereday S, DeFazio A, Bowtell D, et al.
Sci Rep
. 2023 Dec;
13(1):21884.
PMID: 38072854
While the introduction of poly-(ADP)-ribose polymerase (PARP) inhibitors in homologous recombination DNA repair (HR) deficient high grade serous ovarian, fallopian tube and primary peritoneal cancers (HGSC) has improved patient survival,...
9.
Ho G, Vandenberg C, Lim R, Christie E, Garsed D, Lieschke E, et al.
Ther Adv Med Oncol
. 2023 Nov;
15:17588359231208674.
PMID: 38028140
Background: Despite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance; indeed, ~15% of individuals have...
10.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
medRxiv
. 2023 Nov;
PMID: 37986741
Background: Somatic loss of the tumour suppressor RB1 is a common event in tubo-ovarian high-grade serous carcinoma (HGSC), which frequently co-occurs with alterations in homologous recombination DNA repair genes including...